Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Yanqiao Zhang et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
Survival outcomes and safety of nimotuzumab combined with radiotherapy ± chemotherapy for locally advanced cervical cancerJ Y Li, Jingjing Wang, Tao Wu et al.|International Journal of Gynecological Cancer|2025Cited by 1